VolitionRx Q1 2026 revenue $1.0M; $5M milestone potential from feline lymphoma test

VOLITIONRX LTD

2026-Q1 EPS reported -$0.97 revenue$985,076

Revenue of $1.0M in Q1 2026 vs $0.2M in Q1 2025; operating loss decreased 3% YoY.
Net cash used in operations was $5.3M; raised $5.4M from ATM equity and $1.9M from convertible note.
Received $1M in non-dilutive Walloon Region funding; ~$0.9M more expected over 12 months.
Feline lymphoma assay manuscript submitted for peer review; expected to unlock $5M milestone payment.
Discussions ongoing with >12 diagnostic companies for licensing; Nu.Q Lung Cancer reimbursement in France progressing.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.